Table 5.

Comparing genotypic drug susceptibility results of targeted nanopore versus phenotypic drug susceptibility.

Drug	Target genes & mutation sites		Phenotypically susceptible (No. of isolates)	Phenotypically resistant (No. of isolates)	Concordance (%)
Rifampicin	rpoB	Leu511Pro	0	1	100
	rpoB	Ser531Leu	0	2
	rpoB	Ser531Leu, Thr400Ala	0	1
	No mutations detected		15	0
Isoniazid	katG	Ser315Thr	0	3	100
	inhA	– 15 C→T	0	1
	No mutations detected		15	0
Fluoroquinolones	gyrB	Asp94Gly	0	1	100
	gyrB	Ala90Val	0	1
	No mutations detected		17	0
Streptomycin	rpsl	Lys43Arg	0	3	100
	No mutations detected		16	0
Pyrazinamide	pncA	Asp63Gly	1	0	94.7
	pncA	Thr76Ile	0	1
	No mutations detected		17	0
Ethambutol	embB	Tyr319Ser	1	0	89.5
	No mutations detected		17	1
Amikacin	No mutations detected		19	0	-
Capreomycin	No mutations detected		19	0	-
Aminosalicylic acid	No mutations detected		19	0	-
Prothionamide	No mutations detected		19	0	-